Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)· @TiansterZhang · X·· 2 天前评分70
正文 · 机器翻译
#RandySweis 展示了 EV-SG-zim 在一线治疗转移性 #urothelialcancer 的数据 — 样本量虽小但 ORR 高达 81%，其中 3 例患者达到 CR。推动转移性 UC 的反应深度。\n@oncoalert #ESMO26 @myESMO
464 浏览 · 8 赞 · 8 转发 · 0 回复
会议摘要
1017P按 Developmental therapeutics 对上
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663按 - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy 对上
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.org来源：Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) · x.com